![](https://thepharmadata.com/wp-content/uploads/2024/07/argenx-and-Zai-Lab-Announce-Efgartigimod-Alfa-Approval-for-Myasthenia-Gravis-in-China-768x512.webp)
argenx and Zai Lab Announce Efgartigimod Alfa Approval for Myasthenia Gravis in China
Today, argenx and Zai Lab announced that China’s National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) for efgartigimod alfa injection (subcutaneous) on July 16, 2024. This 1,000mg (5.6ml)/vial treatment is indicated as an add-on to standard therapy…